Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000947871-25-001096
Filing Date
2025-12-29
Accepted
2025-12-29 20:44:14
Documents
1
Period of Report
2025-12-24

Document Format Files

Seq Description Document Type Size
1 ownership.html 4  
1 ownership.xml 4 5982
  Complete submission text file 0000947871-25-001096.txt   8130
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Reporting) CIK: 0001055951 (see all company filings)

State of Incorp.: DE
Type: 4 | Act: 34 | File No.: 001-42504 | Film No.: 251610875

Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022-4629
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022-4629 (212) 739-6400
OrbiMed Capital GP VIII LLC (Reporting) CIK: 0001845804 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-42504 | Film No.: 251610874

Mailing Address 21 HICKORY DRIVE, SUITE 500 WALTHAM MA 02451
Business Address 21 HICKORY DRIVE, SUITE 500 WALTHAM MA 02451 617-819-2020
Sionna Therapeutics, Inc. (Issuer) CIK: 0002036042 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)